

Boston Scientific Announces Completion Of Radiotherapeutics Corporation Acquisition.

Print

Date: Dec 12, 2001

Words: 271

Publication: PR Newswire

NATICK, Mass. -- Boston Scientific Corporation today announced the completion of its acquisition of Radiotherapeutics Corporation (RTC). Terms of the agreement were not disclosed. Boston Scientific had announced the signing of a definitive agreement with RTC on November 8.

"We are pleased with the rapid closure of this transaction," said Steve Moreci, President of Boston Scientific's Endosurgery Group. "We are now in a position to integrate our organizations and move forward on our shared goal of providing alternative therapies for cancer patients."

RTC develops and manufactures proprietary radiofrequency-based therapeutic devices in the field of interventional oncology for the ablation (destruction) of various forms of soft-tissue lesions (tumors). The RTC acquisition will expand Boston Scientific's interventional oncology portfolio. Boston Scientific's Medi-tech division is a leading developer of medical technologies used by interventional radiologists, surgical oncologists, and both general and vascular surgeons.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, consummating and integrating acquisitions, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

MAKE YOUR OPINION COUNT - Click Here

<http://tbutton.prnewswire.com/prn/11690X70537185>

Contact: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific Corporation

Website: <http://www.bsci.com/>

2/28/2011

Boston Scientific Announces Completi...

COPYRIGHT 2001 PR Newswire Association LLC

Copyright 2001 Gale, Cengage Learning. All rights reserved.